Market Closed -
Nasdaq
04:00:00 2024-06-07 pm EDT
|
5-day change
|
1st Jan Change
|
22.72
USD
|
+0.66%
|
|
-5.21%
|
+12.14%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,098
|
705.1
|
719.4
|
866.2
|
1,175
|
-
|
-
|
Enterprise Value (EV)
1 |
821.4
|
457.3
|
505.9
|
617.1
|
672.8
|
771.2
|
974.9
|
P/E ratio
|
-4.7
x
|
-8.54
x
|
-6.69
x
|
-7.85
x
|
-7.57
x
|
-7.8
x
|
-7.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
80.7
x
|
39.1
x
|
230
x
|
41.8
x
|
323
x
|
171
x
|
588
x
|
EV / Revenue
|
60.3
x
|
25.4
x
|
162
x
|
29.8
x
|
185
x
|
112
x
|
488
x
|
EV / EBITDA
|
-14.9
x
|
-6.55
x
|
-4.7
x
|
-5.68
x
|
-4.12
x
|
-3.36
x
|
-3.4
x
|
EV / FCF
|
-15.8
x
|
-
|
-5.15
x
|
-7.85
x
|
-4.04
x
|
-4.55
x
|
-5.29
x
|
FCF Yield
|
-6.32%
|
-
|
-19.4%
|
-12.7%
|
-24.8%
|
-22%
|
-18.9%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
26,494
|
32,139
|
32,392
|
42,754
|
51,703
|
-
|
-
|
Reference price
2 |
41.45
|
21.94
|
22.21
|
20.26
|
22.72
|
22.72
|
22.72
|
Announcement Date
|
3/25/21
|
3/28/22
|
3/15/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
13.61
|
18.04
|
3.129
|
20.72
|
3.632
|
6.867
|
1.997
|
EBITDA
1 |
-55.22
|
-69.81
|
-107.6
|
-108.7
|
-163.5
|
-229.8
|
-287.1
|
EBIT
1 |
-56.66
|
-71.33
|
-110
|
-112.9
|
-165.3
|
-211
|
-236.6
|
Operating Margin
|
-416.28%
|
-395.46%
|
-3,516.52%
|
-544.65%
|
-4,551.45%
|
-3,072.56%
|
-11,847.75%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-107.5
|
-100.8
|
-147.9
|
-170.6
|
-186
|
Net income
1 |
-56.69
|
-71.32
|
-107.5
|
-100.8
|
-154.8
|
-190.4
|
-186
|
Net margin
|
-416.49%
|
-395.37%
|
-3,435.41%
|
-486.59%
|
-4,261.77%
|
-2,772.55%
|
-9,314.77%
|
EPS
2 |
-8.820
|
-2.570
|
-3.320
|
-2.580
|
-3.000
|
-2.912
|
-3.070
|
Free Cash Flow
1 |
-51.91
|
-
|
-98.22
|
-78.56
|
-166.6
|
-169.5
|
-184.4
|
FCF margin
|
-381.35%
|
-
|
-3,139.05%
|
-379.11%
|
-4,585.93%
|
-2,468.28%
|
-9,235.13%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/25/21
|
3/28/22
|
3/15/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.092
|
1.219
|
0.162
|
0.5
|
1.247
|
0.298
|
0.239
|
20.2
|
-0.019
|
0.028
|
1.14
|
1.092
|
1.62
|
0.5
|
0.5
|
EBITDA
|
-24.37
|
-
|
-27.96
|
-
|
-
|
-29.08
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-24.76
|
-26.39
|
-28.43
|
-26.5
|
-28.72
|
-30.11
|
-32.14
|
-13.97
|
-36.65
|
-38.14
|
-39.95
|
-42.37
|
-45.14
|
-48
|
-53
|
Operating Margin
|
-26,917.39%
|
-2,165.05%
|
-17,546.91%
|
-5,299%
|
-2,303.13%
|
-10,102.68%
|
-13,446.03%
|
-69.16%
|
192,905.26%
|
-136,200%
|
-3,504.28%
|
-3,880.91%
|
-2,785.92%
|
-9,600%
|
-10,600%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-28.09
|
-25.69
|
-27.38
|
-28.68
|
-29.62
|
-10.26
|
-32.28
|
-32.4
|
-36.7
|
-38.43
|
-40.33
|
-
|
-
|
Net income
1 |
-25.08
|
-26.34
|
-28.09
|
-25.69
|
-27.38
|
-28.68
|
-29.62
|
-10.26
|
-32.28
|
-32.4
|
-36.92
|
-39
|
-46.5
|
-
|
-
|
Net margin
|
-27,264.13%
|
-2,160.62%
|
-17,337.04%
|
-5,138.2%
|
-2,195.59%
|
-9,624.83%
|
-12,391.63%
|
-50.76%
|
169,910.53%
|
-115,717.86%
|
-3,238.76%
|
-3,572.24%
|
-2,869.86%
|
-
|
-
|
EPS
2 |
-0.8500
|
-0.8200
|
-0.8700
|
-0.7900
|
-0.8400
|
-0.8800
|
-0.7700
|
-0.2400
|
-0.7700
|
-0.6600
|
-0.7333
|
-0.7733
|
-0.9200
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/28/22
|
5/12/22
|
8/11/22
|
11/8/22
|
3/15/23
|
5/10/23
|
8/9/23
|
11/9/23
|
2/29/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
277
|
248
|
214
|
249
|
502
|
403
|
200
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-51.9
|
-
|
-98.2
|
-78.6
|
-167
|
-169
|
-184
|
ROE (net income / shareholders' equity)
|
-61.8%
|
-24.8%
|
-39.1%
|
-37.4%
|
-44.6%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-7.920
|
-2.490
|
-2.680
|
-1.940
|
-
|
-
|
-
|
Capex
1 |
1
|
-
|
11.5
|
2.77
|
4.49
|
4.53
|
4.58
|
Capex / Sales
|
7.35%
|
-
|
368.68%
|
13.37%
|
123.57%
|
66.01%
|
229.27%
|
Announcement Date
|
3/25/21
|
3/28/22
|
3/15/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
22.72
USD Average target price
52.3
USD Spread / Average Target +130.19% Consensus |
1st Jan change
|
Capi.
|
---|
| +12.14% | 1.17B | | +51.85% | 57.87B | | +41.42% | 40.25B | | -5.25% | 39.94B | | -5.16% | 28.54B | | +12.79% | 26.4B | | -20.18% | 19.33B | | +30.88% | 12.4B | | +0.61% | 12.23B | | +25.06% | 12.2B |
Other Biotechnology & Medical Research
|